Salix Pharmaceuticals, Ltd. Announces Statistically Significant Top- Line Results for Second Product Registration Study of Granulated Mesalamine in Ulcerative Colitis

RALEIGH, N.C.--(BUSINESS WIRE)--Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced the successful completion and outcome of the second of two Phase III registration trials to evaluate the safety and efficacy of the Company’s new granulated mesalamine product currently under development for the maintenance of remission in patients with ulcerative colitis. Results from the study indicate that a statistically significantly greater proportion of subjects dosed once-a-day with 1.5 grams of granulated mesalamine remained relapse-free over 6 months of treatment than patients dosed with placebo.